Auhtors: Goubran H, Stakiw J, Seghatchian J, Ragab G, Burnouf T
PMID: 35753906 PMCID: PMC9192107 DOI: 10.1016/j.transci.2022.103488
Abstract
The COVID-19 pandemic caused by the SARS-CoV-2 virus has significantly disrupted and burdened the diagnostic workup and delivery of care, including transfusion, to cancer patients across the globe. Furthermore, cancer patients suffering from solid tumors or hematologic malignancies were more prone to the infection and had higher morbidity and mortality than the rest of the population. Major signaling pathways have been identified at the intersection of SARS-CoV-2 and cancer cells, often leading to tumor progression or alteration of the tumor response to therapy. The reactivation of oncogenic viruses has also been alluded to in the context and following COVID-19. Paradoxically, certain tumors responded better following the profound infection-induced immune modulation. Unveiling the mechanisms of the virus-tumor cell interactions will lead to a better understanding of the pathophysiology of both cancer progression and virus propagation. It would be challenging to monitor, through the different cancer registries, retrospectively, the response of patients who have been previously exposed to the virus in contrast to those who have not contracted the infection.
Keywords: COVID-19; Cancer; Cross-talk; SARS-CoV-2.
Source: https://pubmed.ncbi.nlm.nih.gov/35753906/
Archive: https://archive.is/awIY5
